-
11:08:00 PM

PBYI Stock News

09/21/23 4:10 PM
Nasdaq : PBYI
clinical trial
Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer
Puma Biotechnology, Inc., a biopharmaceutical company, announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to alisertib, a selective, small-molecule, orally administered inhibitor of aurora kinase A, for the treatment of patients with small cell lung cancer. The FDA grants Orphan Drug Designation to investigational...
RHEA-AI
positive
08/31/23 4:07 PM
Nasdaq : PBYI
conferences
Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Puma Biotechnology, Inc., a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at the hybrid H.C. Wainwright 25 th Annual Global Investment Conference, which will be held September 11-13, 2023. Neratinib, oral was approved by the U.S. Food and Drug...
RHEA-AI
very positive
08/08/23 8:30 AM
Nasdaq : PBYI
clinical trial
Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer
Puma Biotechnology, Inc., a biopharmaceutical company, has been notified by the U.S. Food and Drug Administration that its Investigational New Drug submission has been reviewed, and Puma can proceed with the clinical development of alisertib monotherapy for the treatment of patients with extensive stage small cell lung cancer. Puma’ s Phase II trial will...
RHEA-AI
positive
07/20/23 4:15 PM
Nasdaq : PBYI
conferencesearnings
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results
Puma Biotechnology, Inc., a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4: 30 p.m. EDT on Thursday, August 3, 2023, following the release of its second quarter 2023 financial results. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage...
RHEA-AI
very positive
06/04/23 9:00 AM
Nasdaq : PBYI
clinical trial
Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting
Puma Biotechnology, Inc., a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II study of alisertib plus paclitaxel versus paclitaxel alone in metastatic hormone receptor positive and triple negative breast cancer at the 2023 American Society of Clinical Oncology Annual Meeting held June 2-6 in Chicago and online.
RHEA-AI
very positive
04/20/23 4:15 PM
Nasdaq : PBYI
conferencesearnings
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results
Puma Biotechnology, Inc., a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/ 4:30 p.m. EDT on Thursday, May 4, 2023, following the release of its first quarter 2023 financial results. Please dial in at least 10 minutes in advance and inform the operator that you would like to join the“ Puma Biotechnology Conference Call.” A live webcast of the...
RHEA-AI
neutral